Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D
Journal of Medicinal Chemistry2010Vol. 53(15), pp. 5422–5438
Citations Over TimeTop 11% of 2010 papers
Erik L. Meredith, Kimberly Beattie, Robin Burgis, Michael Capparelli, Joseph Chapo, Lucian DiPietro, Gabriel G. Gamber, Istvan Enyedy, David B. Hood, Vinayak Hosagrahara, Charles Jewell, Keith A. Koch, Wendy Lee, Douglas D. Lemon, Timothy A. McKinsey, Karl Miranda, Nikos Pagratis, Dillon Phan, Craig F. Plato, Chang Rao, Olga Rozhitskaya, Nicolas Soldermann, Clayton Springer, Maurice van Eis, Richard B. Vega, Wanlin Yan, Qingming Zhu, Lauren G. Monovich
Abstract
The synthesis and biological evaluation of potent and selective PKD inhibitors are described herein. The compounds described in the present study selectively inhibit PKD among other putative HDAC kinases. The PKD inhibitors of the present study blunt phosphorylation and subsequent nuclear export of HDAC4/5 in response to diverse agonists. These compounds further establish the central role of PKD as an HDAC4/5 kinase and enhance the current understanding of cardiac myocyte signal transduction. The in vivo efficacy of a representative example compound on heart morphology is reported herein.
Related Papers
- → HDAC4 deacetylase associates with and represses the MEF2 transcription factor(1999)572 cited
- → Regulation of Histone Deacetylase 4 by Binding of 14-3-3 Proteins(2000)284 cited
- → HDAC4 Does Not Act as a Protein Deacetylase in the Postnatal Murine Brain In Vivo(2013)32 cited
- → The posttranslational modification of HDAC4 in cell biology: Mechanisms and potential targets(2019)25 cited
- → Roles of mammalian sterile 20‐like kinase 2‐dependent phosphorylations of Mps one binder 1B in the activation of nuclear Dbf2‐related kinases(2009)21 cited